Related Experiment Video
Updated: Jul 15, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Coenzyme Q10 in cardiovascular disease
Salvatore Pepe1, Silvana F Marasco, Steven J Haas
1CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia.
Abstract:
In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Cardiomyopathy VI: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Heart Failure Drugs: Inotropic Agents
